Clinical and Experimental Pediatrics (Apr 2020)

Variation in clinical usefulness of biomarkers of acute kidney injury in young children undergoing cardiac surgery

  • Hee Sun Baek,
  • Youngok Lee,
  • Hea Min Jang,
  • Joonyong Cho,
  • Myung Chul Hyun,
  • Yeo Hyang Kim,
  • Su-Kyeong Hwang,
  • Min Hyun Cho

DOI
https://doi.org/10.3345/cep.2019.00913
Journal volume & issue
Vol. 63, no. 4
pp. 151 – 156

Abstract

Read online

Background Acute kidney injury (AKI) is one of the most significant postoperative complications of pediatric cardiac surgery. Because serum creatinine has limitations as a diagnostic marker of AKI, new biomarkers including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) are being evaluated to overcome these limitations and detect AKI at an early stage after cardiac surgery. Purpose This study aimed to investigate the clinical usefulness of these biomarkers in young children. Methods Thirty patients with congenital heart diseases who underwent cardiac surgery using cardiopulmonary bypass (CPB) were selected, and their urine and blood samples were collected at baseline and 6, 24, and 48 hours after surgery. Serum creatinine and blood urea nitrogen levels as well as NGAL, KIM-1, and IL-18 levels in urine samples were measured, and clinical parameters were evaluated. Results Of the 30 patients, 12 developed AKI within 48 hours after cardiac surgery. In the AKI group, 8 of 12 (66.6%) met AKI criteria after 24 hours, and urine KIM-1/creatinine (Cr) level (with adjustment of urine creatinine) peaked at 24 hours with significant difference from baseline level. Additionally, urine KIM-1/Cr level in the AKI group was significantly higher than in the non-AKI group at 6 hours. However, urine NGAL/Cr and IL-18/Cr levels showed no specific trend with time for 48 hours after cardiac surgery. Conclusion It is suggested that urine KIM-1/Cr concentration could be considered a good biomarker for early AKI prediction after open cardiac surgery using CPB in young children with congenital heart diseases.

Keywords